MX2007016528A - Metodos y composiciones para diagnosticos y monitoreo de enfermedad cardiovascular aterosclerotica. - Google Patents

Metodos y composiciones para diagnosticos y monitoreo de enfermedad cardiovascular aterosclerotica.

Info

Publication number
MX2007016528A
MX2007016528A MX2007016528A MX2007016528A MX2007016528A MX 2007016528 A MX2007016528 A MX 2007016528A MX 2007016528 A MX2007016528 A MX 2007016528A MX 2007016528 A MX2007016528 A MX 2007016528A MX 2007016528 A MX2007016528 A MX 2007016528A
Authority
MX
Mexico
Prior art keywords
proteins
cardiovascular disease
atherosclerotic cardiovascular
diagnosis
compositions
Prior art date
Application number
MX2007016528A
Other languages
English (en)
Inventor
Raymond Tabibiazar
Philip S Tsao
Thomas Quertermous
Brit Katzen Turnbull
Richard A Olshen
Evangelos Hytopoulos
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2007016528A publication Critical patent/MX2007016528A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Data Mining & Analysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Databases & Information Systems (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invencion identifica proteinas circulatorias que son de manera diferente expresadas en aterosclerosis. Los niveles circulatorios de estas proteinas, particularmente como un panel de proteinas, pueden discriminar a los pacientes con infarto de miocardio agudo de los pacientes con agina por esfuerzo estable y de los pacientes sin historia de enfermedad cardiovascular aterosclerotica. Estos niveles pueden predecir los eventos cardiovasculares, determinar la efectividad de la terapia, la etapa de la enfermedad, y similares. Por ejemplo, estos marcadores son utiles como biomarcadores de eventos clinicos que se necesitan para el desarrollo de agentes farmaceuticos especificos vasculares.
MX2007016528A 2005-06-24 2006-06-26 Metodos y composiciones para diagnosticos y monitoreo de enfermedad cardiovascular aterosclerotica. MX2007016528A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69375605P 2005-06-24 2005-06-24
US11/473,826 US20070099239A1 (en) 2005-06-24 2006-06-23 Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
PCT/US2006/025003 WO2007002677A2 (en) 2005-06-24 2006-06-26 Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease

Publications (1)

Publication Number Publication Date
MX2007016528A true MX2007016528A (es) 2008-04-10

Family

ID=37595982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007016528A MX2007016528A (es) 2005-06-24 2006-06-26 Metodos y composiciones para diagnosticos y monitoreo de enfermedad cardiovascular aterosclerotica.

Country Status (8)

Country Link
US (1) US20070099239A1 (es)
EP (1) EP1913388A4 (es)
JP (1) JP2009501318A (es)
AU (1) AU2006261779A1 (es)
CA (1) CA2613584A1 (es)
IL (1) IL188231A0 (es)
MX (1) MX2007016528A (es)
WO (1) WO2007002677A2 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006093932A2 (en) * 2005-03-01 2006-09-08 Cedars-Sinai Medical Center Use of eotaxin as a diagnostic indicator for atherosclerosis and vascular inflammation
US20070292880A1 (en) * 2006-05-05 2007-12-20 Robert Philibert Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome
WO2007146229A2 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
US20080020982A1 (en) * 2006-07-21 2008-01-24 Patrice Delafontaine Methods and compositions for treatment of atherosclerosis
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
US20080300798A1 (en) * 2007-04-16 2008-12-04 Mcdevitt John T Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics
US20090029372A1 (en) * 2007-05-14 2009-01-29 Kobenhavns Universitet Adam12 as a biomarker for bladder cancer
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
US8431367B2 (en) 2007-09-14 2013-04-30 Predictive Biosciences Corporation Detection of nucleic acids and proteins
US8852893B2 (en) 2007-09-14 2014-10-07 Physicians Choice Laboratory Services, Llc Detection of nucleic acids and proteins
US7955822B2 (en) * 2007-09-14 2011-06-07 Predictive Biosciences Corp. Detection of nucleic acids and proteins
US20100267041A1 (en) * 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
US20090204338A1 (en) * 2008-02-13 2009-08-13 Nordic Bioscience A/S Method of deriving a quantitative measure of the instability of calcific deposits of a blood vessel
JP5574990B2 (ja) * 2008-03-10 2014-08-20 リニーゲン、インコーポレイテッド Ｃｏｐｄバイオマーカーシグネチャー
US8285719B1 (en) 2008-08-08 2012-10-09 The Research Foundation Of State University Of New York System and method for probabilistic relational clustering
US11857293B2 (en) 2008-10-29 2024-01-02 Flashback Technologies, Inc. Rapid detection of bleeding before, during, and after fluid resuscitation
US11406269B2 (en) 2008-10-29 2022-08-09 Flashback Technologies, Inc. Rapid detection of bleeding following injury
US11395594B2 (en) 2008-10-29 2022-07-26 Flashback Technologies, Inc. Noninvasive monitoring for fluid resuscitation
US8512260B2 (en) 2008-10-29 2013-08-20 The Regents Of The University Of Colorado, A Body Corporate Statistical, noninvasive measurement of intracranial pressure
US11382571B2 (en) 2008-10-29 2022-07-12 Flashback Technologies, Inc. Noninvasive predictive and/or estimative blood pressure monitoring
EP2356579B1 (en) * 2008-10-29 2015-05-20 The Regents of the University of Colorado, a body corporate Long term active learning from large continually changing data sets
US11478190B2 (en) 2008-10-29 2022-10-25 Flashback Technologies, Inc. Noninvasive hydration monitoring
US11395634B2 (en) 2008-10-29 2022-07-26 Flashback Technologies, Inc. Estimating physiological states based on changes in CRI
EP2406401A4 (en) 2009-03-12 2013-01-09 Cancer Prevention & Cure Ltd METHODS OF IDENTIFYING, ASSESSING, PREVENTING AND THERAPYING LUNG DISEASES AND THEIR KITS COMPRISING IDENTIFICATION, EVALUATION, PREVENTION AND THERAPY OF SEX BASED DISEASES
TWI532842B (zh) * 2009-06-11 2016-05-11 力博美科股份有限公司 針對凝乳酶之適體及其用途
AU2010319290A1 (en) * 2009-11-13 2012-05-24 Bg Medicine, Inc. Risk factors and prediction of myocardial infarction
US20110129131A1 (en) * 2009-11-30 2011-06-02 General Electric Company System and method for integrated quantifiable detection, diagnosis and monitoring of disease using population related time trend data and disease profiles
US20110129129A1 (en) * 2009-11-30 2011-06-02 General Electric Company System and method for integrated quantifiable detection, diagnosis and monitoring of disease using population related data for determining a disease signature
US9271651B2 (en) * 2009-11-30 2016-03-01 General Electric Company System and method for integrated quantifiable detection, diagnosis and monitoring of disease using patient related time trend data
US20110129130A1 (en) * 2009-11-30 2011-06-02 General Electric Company System and method for integrated quantifiable detection, diagnosis and monitoring of disease using population related time trend data
CN102762743A (zh) * 2009-12-09 2012-10-31 阿维埃尔公司 用于心血管疾病的诊断和分类的生物标记物检验
WO2011109503A1 (en) * 2010-03-02 2011-09-09 The Trustees Of The University Of Pennsylvania Novel csf biomarkers for alzheimer's disease and frontotemporal lobar degeneration
JP5786020B2 (ja) 2010-04-16 2015-09-30 アボットジャパン株式会社 関節リウマチを診断する方法および試薬
EP2405271A1 (en) 2010-07-06 2012-01-11 Bio-Rad Innovations Markers of vulnerability of the atherosclerosis plaque
US8676739B2 (en) * 2010-11-11 2014-03-18 International Business Machines Corporation Determining a preferred node in a classification and regression tree for use in a predictive analysis
WO2012070969A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Диагностический способ для прогноза развития и контроля эффективности лечения сердечно-сосудистых заболеваний
CA2834383A1 (en) 2011-04-29 2012-11-01 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
WO2013016212A1 (en) 2011-07-22 2013-01-31 Flashback Technologies, Inc. Hemodynamic reserve monitor and hemodialysis control
CN107102151A (zh) * 2011-09-30 2017-08-29 私募蛋白质体公司 心血管危险事件预测及其用途
US20150027950A1 (en) * 2012-03-27 2015-01-29 Marv Enterprises, LLC Treatment for atherosclerosis
EP2648133A1 (fr) * 2012-04-04 2013-10-09 Biomerieux Identification de microorganismes par spectrometrie et classification structurée
JP6075973B2 (ja) * 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
WO2015171272A1 (en) * 2014-05-06 2015-11-12 Felder Mitchell S Method for treating muscular dystrophy
JP2017530356A (ja) * 2014-09-26 2017-10-12 ソマロジック, インコーポレイテッドSomaLogic, Inc. 心血管系のリスクイベントの予測及びその使用
WO2016141347A2 (en) * 2015-03-04 2016-09-09 Wayne State University Systems and methods to diagnose sarcoidosis and identify markers of the condition
KR101730923B1 (ko) * 2015-07-27 2017-05-02 한국기초과학지원연구원 퓨린 대사체를 이용한 심혈관질환 진단 및 예후 예측 방법
US10299751B2 (en) 2016-03-16 2019-05-28 General Electric Company Systems and methods for color visualization of CT images
US10475217B2 (en) 2016-03-16 2019-11-12 General Electric Company Systems and methods for progressive imaging
CN105954451B (zh) * 2016-06-06 2017-12-26 广东中烟工业有限责任公司 基于电子鼻全色谱数据的卷烟类型快速判别方法
WO2018074497A1 (ja) * 2016-10-19 2018-04-26 公立大学法人横浜市立大学 抗動脈硬化剤及び動脈硬化の病態判定方法
WO2018094204A1 (en) * 2016-11-17 2018-05-24 Arivale, Inc. Determining relationships between risks for biological conditions and dynamic analytes
JP7250693B2 (ja) 2017-04-04 2023-04-03 ラング キャンサー プロテオミクス， エルエルシー 初期ステージの肺がん診断のための血漿ベースのタンパク質プロファイリング
AU2018392605A1 (en) * 2017-12-19 2020-07-30 Chase Therapeutics Corporation Methods for developing pharmaceuticals for treating neurodegenerative conditions
CN110090002A (zh) * 2018-06-21 2019-08-06 北京大学 一种小鼠前额叶神经元双光子荧光钙信号的自动检测方法
US11918386B2 (en) 2018-12-26 2024-03-05 Flashback Technologies, Inc. Device-based maneuver and activity state-based physiologic status monitoring
RU2747510C1 (ru) * 2019-12-26 2021-05-06 федеральное государственное бюджетное образовательное учреждение высшего образования "Хакасский государственный университет им. Н.Ф. Катанова" (ФГБОУ ВО ХГУ им. Н.Ф. Катанова) Способ оценки риска развития атеросклероза на основании определения сывороточного уровня интерлейкина-5
EP4338163A4 (en) * 2021-05-13 2024-11-06 Scipher Medicine Corp EVALUATION OF RESPONSIVENESS TO TREATMENT
CN113484453B (zh) * 2021-07-07 2022-08-09 天津中医药大学 一种缺血性脑卒中预警方法
CN114720582B (zh) * 2021-11-26 2023-10-20 韩山师范学院 一种不同陈化年份老香黄的综合评价方法
WO2023224948A1 (en) * 2022-05-16 2023-11-23 Attia Itzhak Zachi Deep learning enabled electrocardiographic prediction of computer tomography-based high coronary calcium score (cac)

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US238889A (en) * 1881-03-15 Thill-holder
US5792450A (en) * 1985-02-05 1998-08-11 Chiron Corporation Purified human CSF-1
WO1986004607A1 (en) * 1985-02-05 1986-08-14 Cetus Corporation Recombinant colony stimulating factor-1
US5304637A (en) * 1987-07-13 1994-04-19 Gist-Brocades N.V. Expression and purification of human interleukin-3 and muteins thereof
US6384194B1 (en) * 1987-12-16 2002-05-07 Dsm N.V. Expression and purification of human interleukin-3 and muteins thereof
US6869924B1 (en) * 1989-01-31 2005-03-22 The United States Of America As Represented By The Department Of Health And Human Services Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof
IL92937A0 (en) * 1989-01-31 1990-09-17 Us Health Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it
ATE344324T1 (de) * 1993-09-14 2006-11-15 Imp Innovations Ltd Eotaxin = eosinophil chemotaktisches cytokin
US6174995B1 (en) * 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6458349B1 (en) * 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US7265201B1 (en) * 1995-06-23 2007-09-04 Millennium Pharmaceuticals, Inc. Human chemotactic cytokine
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
ATE530180T1 (de) * 1997-04-02 2011-11-15 Brigham & Womens Hospital Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
US20030149997A1 (en) * 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6703202B2 (en) * 1999-11-30 2004-03-09 Oxo Chemie Ag Evaluating and predicting clinical outcomes by gene expression analysis
EP1120576B1 (en) * 2000-01-24 2003-11-12 Eric Thompson Toolless locking mount
DE60136527D1 (de) * 2000-03-03 2008-12-24 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
US6946546B2 (en) * 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
GB0005867D0 (en) * 2000-03-10 2000-05-03 Medinnova Sf Method
WO2002000933A2 (en) * 2000-06-23 2002-01-03 Interleukin Genetics, Inc. Screening assays for identifying modulators of the inflammatory or immune responses
US20050154407A1 (en) * 2000-12-20 2005-07-14 Fox Hollow Technologies, Inc. Method of evaluating drug efficacy for treating atherosclerosis
US6768756B2 (en) * 2001-03-12 2004-07-27 Axsun Technologies, Inc. MEMS membrane with integral mirror/lens
KR20030094281A (ko) * 2001-03-12 2003-12-11 모노젠, 인크. 세포에 기초한 질병상태의 검출 및 질병상태의 구별
US20030199000A1 (en) * 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20040121350A1 (en) * 2002-12-24 2004-06-24 Biosite Incorporated System and method for identifying a panel of indicators
US20030166903A1 (en) * 2001-04-27 2003-09-04 Anna Astromoff Genes associated with vascular disease
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20040209307A1 (en) * 2001-08-20 2004-10-21 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7608406B2 (en) * 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
EP1419388B1 (en) * 2001-08-20 2009-10-07 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
EP1451580B1 (en) * 2001-11-09 2009-07-08 Medstar Research Institute Method of using physiological markers to estimate cardiovascular risk
US20060141493A1 (en) * 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
AR037456A1 (es) * 2001-11-30 2004-11-10 Biogen Inc Anticuerpos contra proteinas quimiotacticas monocitarias
WO2003091391A2 (en) * 2002-04-23 2003-11-06 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
AUPS194902A0 (en) * 2002-04-24 2002-06-06 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
RS20050834A (en) * 2002-08-19 2007-12-31 Abgenix Inc., Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
WO2004059293A2 (en) * 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20050181386A1 (en) * 2003-09-23 2005-08-18 Cornelius Diamond Diagnostic markers of cardiovascular illness and methods of use thereof
US7634360B2 (en) * 2003-09-23 2009-12-15 Prediction Sciences, LL Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
CA2832293C (en) * 2003-11-26 2015-08-04 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
WO2005116268A2 (en) * 2004-05-27 2005-12-08 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Differential expression of molecules associated with acute stroke
CA2587143C (en) * 2004-12-08 2017-12-05 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer

Also Published As

Publication number Publication date
EP1913388A4 (en) 2010-10-20
AU2006261779A1 (en) 2007-01-04
EP1913388A2 (en) 2008-04-23
CA2613584A1 (en) 2007-01-04
IL188231A0 (en) 2008-03-20
JP2009501318A (ja) 2009-01-15
WO2007002677A3 (en) 2009-04-23
WO2007002677A2 (en) 2007-01-04
US20070099239A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
MX2007016528A (es) Metodos y composiciones para diagnosticos y monitoreo de enfermedad cardiovascular aterosclerotica.
WO2008080126A3 (en) Two biomarkers for diagnosis and monitoring of atherosclerotic cardiovascular disease
CY1120296T1 (el) ΔΙΑΛΥΤΟΣ ΥΠΟΔΟΧΕΑΣ ΕΝΕΡΓΟΠΟΙΗΤΗ ΤΟΥ ΠΛΑΣΜΙΝΟΓΟΝΟΥ ΤΥΠΟΥ ΟΥΡΟΚΙΝΑΣΗΣ (suPAR) ΩΣ ΔΙΑΓΝΩΣΤΙΚΟΣ ΔΕΙΚΤΗΣ ΓΙΑ ΧΑΜΗΛΟΥ ΒΑΘΜΟΥ ΦΛΕΓΜΟΝΗ
Troughton et al. Natriuretic peptide-guided heart failure management
Ten Cate et al. Thrombin generation and atherothrombosis: what does the evidence indicate?
ATE517341T1 (de) Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
WO2002089657A3 (en) Diagnostic markers of acute coronary syndromes and methods of use thereof
Bach et al. Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk
EP2543389A3 (en) Methods and compositions inhibiting a lysyl oxidase (-like) protein for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2004059293A3 (en) Markers for differential diagnosis and methods of use thereof
Boffa et al. Update on lipoprotein (a) as a cardiovascular risk factor and mediator
EP3284469A3 (en) Compositions and methods for detection of lysosomal storage disease
Firoz et al. Neopterin: An immune biomarker of coronary artery disease and its association with other CAD markers
Freedman et al. APOL1 renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial
WO2004089184A3 (en) NEW USES OF Lp-PLA2 IN COMBINATION TO ASSESS CORONARY RISK
FR2886941B1 (fr) Procede d'hydrocraquage doux incluant une dilution de la charge
Fløe et al. Genotyping increases the yield of angiotensin-converting enzyme in sarcoidosis–a systematic review
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
Tripodi et al. More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required
EA201491411A1 (ru) Растворимый manf при поражениях бета-клеток поджелудочной железы
Arai et al. The I4399M variant of apolipoprotein (a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles
WO2007143183A3 (en) Methods for developing and assessing therapeutic agents
DE602004023766D1 (de) Dot1-histon-methyltransferasen als ziel zur identifizierung von therapeutika gegen leukämie
Boekholdt et al. Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events

Legal Events

Date Code Title Description
FA Abandonment or withdrawal